Nurix Therapeutics Shares Plunge on Sanofi's Termination of Drug Development Program
By Elias Schisgall
Shares of Nurix Therapeutics plunged after the company said Sanofi was terminating a drug development program under the two companies' collaboration agreement.
Shares fell 34% to $17.07 in after-hours trading on Tuesday. The stock closed up 0.5% at $25.82, up 36% this year.
Sanofi notified Nurix that it was discontinuing a phase 1 trial for SAR448272 and terminating the SAR448272 research program, Nurix said Tuesday. The decision means Nurix does not expect to receive any future development, regulatory, and commercial milestone payments or royalties from the program.
"While today's news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline," Chief Executive Officer Arthur Sands said.
Nurix said it remains eligible for future milestone payments and royalties associated with other licensed programs developed under the agreement with Sanofi.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
November 03, 2026 17:11 ET (22:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States